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Abstract The sensitivity of lymph node core-needle biopsy
under imaging guidance requires validation. We employed
power Doppler ultrasonography (PDUS) to select the lymph
nodemost suspected of malignancy and to histologically char-
acterize it through the use of large cutting needle. Institutional
review board approval and informed consent were obtained
for this randomized clinical trial. In a single center between 1
January 2009 and 31 December 2015, patients with lymph
node enlargement suspected for lymphoma were randomly
assigned (1:1) to biopsy with either standard surgery or
PDUS-guided 16-gauge modified Menghini needle. The pri-
mary endpoint was the superiority of sensitivity for the diag-
nosis of malignancy for core-needle cutting biopsy (CNCB).
Secondary endpoints were times to biopsy, complications, and
costs. A total of 376 patients were randomized into the two
arms and received allocated biopsy. However, four patients
undergoing CNCB were excluded for inadequate samples;
thus, 372 patients were analyzed. Sensitivity for the detection
of malignancy was significantly better for PDUS-guided
CNCB [98.8%; 95% confidence interval (CI), 95.9–99.9] than
standard biopsy (88.7%; 95% CI, 82.9–93; P < 0.001). For all
secondary endpoints, the comparison was significantly disad-
vantageous for conventional approach. In particular, estimated
cost per biopsy performed with standard surgery was 24-fold
higher compared with that performed with CNCB. The pres-
ence of satellite enlarged reactive and/or necrotic lymph nodes
may impair the success of an open surgical biopsy (OSB).
PDUS and CNCB with adequate gauge are diagnostic tools
that enable effective, safe, fast, and low-cost routine biopsy for
patients with suspected lymphoma, avoiding psychological
and physical pain of an unnecessary surgical intervention.
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Introduction
In the case of clinical suspicion of lymphoma, the histological
examination of lymphadenopathy is essential for defining a
correct diagnosis and for developing a proper treatment plan
[1]. An open surgical biopsy (OSB) is still the Bgold
standard,^ owing to the large amount of tissue obtained [2].
Preoperative evaluation includes (1) a careful and through
physical examination, i.e., palpation of superficial lymph node
regions performed by a physician experienced in the manage-
ment of patients with lymphoma; (2) gray-scale ultrasonogra-
phy scans (US), i.e., a technology that is readily available in
clinical practice and is considered to provide sufficient infor-
mation for selecting the node to be biopsied [1, 2]; and (3)
computed tomography (CT), performed to strengthen the sus-
picion of lymphoma [2]. However, the possible presence of
enlarged reactive or necrotic lymph nodes and/or of
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nonpalpable but histologically significant malignant lymph
nodes may impair the success of an OSB. Another limitation
is mostly related to patients whose conditions may be too un-
stable for undergoing general anesthesia and surgical interven-
tion [3]. Thus, a study that has value to decide the primary
interventionist diagnostic tool for suspected lymphoma is a clin-
ically important topic. New mini-invasive approaches to this
procedure based on imaging-guidedmethods are now available.
The introduction of the new generation of ultrasonographic
and biopsy needle devices, which already have been proven
valuable in the management of patients with lymphoma in our
cancer center [4–8], provides the opportunity to develop ef-
fective combined diagnostic strategy. The modern US instru-
ments merge tissue harmonic compound, which generates an
image from multiple imaging lines that strike the target from
different angles [9], with power Doppler (PD) which allows
the study of the angioarchitecture of lymph node tissue [5, 6,
8, 10]. Neoplastic angiogenesis such as vessel proliferation
(endothelial cell migration and proliferation) and abnormal
vascularization (tube formation with stenosis, occlusion,
and/or dilation and/or arteriovenous shunts) is recognized as
being critical for B cell lymphoma pathogenesis [11, 12].
Power Doppler ultrasonography (PDUS) equipment detects
fine flow signals, mimicking an angiography of microvascular
intranodal network. The result is a high-resolution quality ex-
amination that allows better detection of both superficial and
deep-seated malignant lymphadenopathies compared with re-
sults obtained with gray-scale US [13]. Regarding biopsy nee-
dle devices, the latest Menghini needles have ultrathin sharp-
ened cannula with trocar stylet and automatic aspiration with
tiny battery-powered vacuum [14]. These characteristics make
particularly effective the needle devices with large gauge [15].
Under PDUS guidance, the tip of cutting needle can be careful
positioning into the most significant target, obtaining histolog-
ical suction of the core of nodal lesion [14–16]. Nevertheless,
few clear indications for performing such procedure are avail-
able. The Lugano classification for initial evaluation, staging,
and response assessment of Hodgkin and non-Hodgkin lym-
phoma recommend core-needle biopsy when surgical inter-
vention is not possible and to document relapse [2].
However, the existing guidelines are not evidence based, a
uniform program for optimal imaging guidance is lacking,
and the characteristics of biopsy needle, i.e., gauge, length,
tip configurations, and samplingmechanisms, are still a matter
of opinion among experts [1, 14, 16]. Thus, this approach
requires validation with randomized studies.
Our trial was intended to test the efficacy of PDUS-guided
core-needle cutting biopsy (CNCB) compared with OSB as
first-line diagnostic approach for pathologic lymphadenopa-
thies in patients with clinical suspicion of lymphoma. The
primary endpoint of the study was the sensitivity for diagnosis
of malignancy for each of the two interventionist methods,
i.e., percutaneous biopsy by using modified Menghini needle
under modern US guidance and standard excisional biopsy.
Additional endpoints were times to biopsy, rates of biopsy-
related complications, and costs.
Materials and methods
Trial design and participants
Included patients were randomly assigned at 1:1 allocation
ratio to receive lymph node biopsy by using one of two
methods, OSB (standard group) or PDUS-guided CNCB
(core-needle group).
Patients were required to meet the following eligibility
criteria: (a) age ≥14 years, (b) lymph node enlargement clini-
cally suspected for lymphoma, and (c) indication to perform
nodal biopsy. Patients affected by Epstein-Barr virus, cyto-
megalovirus, herpes simplex virus, rubella, toxoplasma, or
tuberculosis infection, as well as abnormalities of coagulation
tests were excluded.
This was a single center study. Eligible patients were reg-
istered at the Hematology Division Office of the BFederico II^
University of Naples, where the trial was designed and ap-
proved by the local Institutional Review Board in the early
2008 (10 January 2008; number of registration, 140/2008).
Interventions
Standard group
In the standard group, all biopsy-related procedures were per-
formed by surgeons experienced in lymph node resection. The
patients underwent physical examination and gray-scale US,
of whom findings were sufficient to account for the region to
be biopsied according to conventional methods [17]. At sur-
geon’s discretion, biopsy was directed to the most superficial
and/or largest lymph node. In a day hospital regimen or as
inpatients, and under local or general anesthesia (according
to the type of intervention scheduled), the lymph nodes were
harvested through skin crease incision obtained by free-hand
methods. Superficial lymphadenopathy was removed by
means of excisional biopsy. Mini-cervicotomy or
mediastinotomy were used for removing lymphadenopathy
in the anterosuperior mediastinum, and abdominal and pelvic
lymphadenopathies were removed by means of laparotomy.
Core-needle group
In the core-needle group, all biopsy-related procedures were
performed by two members of the hematology staff (N.
Pugliese and M. Picardi, with more than 10 years of experi-
ence with interventionist PDUS) [4, 5]. The lymph node to
undergone CNCB was determined by PDUS assessment as
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already reported [8]. In particular, baseline US exploration of all
superficial, anterosuperior mediastinum (clavicular, supra-aor-
tic, and prevascular regions), and abdominal and pelvic lymph
node areas was carried out. Then, any abnormal [for size (long
axis ≥ 2 cm), round shape, hilus absent, and/or hypoechoic
parenchyma] lymph node underwent power Doppler examina-
tion in accordance with methods already described [5, 6, 8],
using a scanner (iU22; Philips Health-care, Bothell, Wash)
equipped with tissue harmonic compound technology
(SonoCT; Philips), power Doppler sonography, and 5–1 MHz
(C5-1 curvilinear; Philips) and 9–3 MHz (L9-3 linear; Philips)
broadband probes. The main criterion to select the node to be
biopsied was the hypervascularization, i.e., intranodal arterial
vessels with high-resistive index value (>0.6) [6, 8]. All CNCB
were carried out under US guidance with a puncture adaptor, an
aseptic technique (sterile cover of the probe and sterile gel), and
cutaneous anesthesia, using a 16-gauge diameter modified
Menghini needle 150 mm in length with automatic aspiration
(Biomol® HS-Hospital; Rome, Italy).
Reference standard
The reference standard for lymph node involvement was his-
topathologic examination. It was performed in a single pathol-
ogy unit by at least three expert hematopathologists (I.
Cozzolino, G. Ciancia, G. Pettinato, P. Zeppa, and/or V.
Varone, with more than 10 years of experience with
hematopathological analysis) [5]. Lymph node samples were
routinely fixed in formalin and embedded in paraffin (FFEP).
The histologic sections were stained according to standard
methods (hematoxylin and eosin, and Giemsa). All cases of
lymphoma were diagnosed by a combination of morphologic,
immunohistochemical and/or molecular analyses and were
classified according to the current WHO criteria [1].
Immunophenotyping was carried out in FFEP slides with an-
tibodies recognizing CD3, CD4, CD8, CD5, CD10, CD15,
CD20, CD23, CD30, CD45RB, CD56, CD79a, bcl-2, bcl-6,
cyclin D1, PAX-5, Mum-1, Ki-67, ALK-1, and TdT. Bcl-2,
Myc, Cyclin D1, and MALT-1 gene translocations were eval-
uated by fluorescent in situ hybridization analysis in FFPE
slides using commercially available kits, whenever deemed
necessary. B or T cell clonality was also investigated by poly-
merase chain reaction. Epithelial metastatic tumors were iden-
tified by monoclonal antibodies to cytokeratin.
Overall, biopsies were categorized as positive for malig-
nancy (samples containing adequate number of cells with
morphologic atypia and evidence of monoclonality), negative
for malignancy (samples containing adequate number of cells
with no evidence of malignancy), or inadequate (specimens
too small to confirm or rule out malignancy). Patients classi-
fied as having histologic results negative for malignancy
underwent strict follow-up by clinicians for the following
months, in order to discovery a malignant disease undetected
at first biopsy.
In 50 patients of the experimental arm, the biopsy speci-
mens of nodal tissue were studied by the three operators: each
one was blinded to the patient’s clinical condition and to the
histologic results of the other hematopathologists (interob-
server reproducibility) [15].
Primary and secondary outcomes
The sensitivity for each arm was defined as the ratio of pa-
tients who showed lymph node positive for malignancy at first
biopsy compared with the total number of patients with ma-
lignancy. In addition, the negative predictive value was de-
fined as the ratio of patients with lymph node negative for
malignancies at first biopsy compared to the total number of
patients with negative results for malignancy during the fol-
low-up. The likelihood ratio of a negative test was also calcu-
lated (1 minus sensitivity divided by specificity).
The waiting time for the performance of biopsy was calcu-
lated as the number of days elapsed between indication to
lymph node biopsy and the execution of the procedure itself.
After biopsy, patients were strictly monitored in order to
look for procedure-related complications. Outpatients were
kept under observation for 1 h and were discharged if there
were no signs or symptoms suggestive of a significant com-
plication. All patients were encouraged to contact their physi-
cians if they developed symptoms after leaving hospital.
Cost analysis for biopsy procedures was performed by
adopting the perspective of the National Healthcare System.
Cost calculations for PDUS-guided CNCB were based on the
tariffs in the Nomenclature for Outpatient Care, provided by
the Italian National Healthcare System (http://www.arsan.
campania.it/documents/10157/01088316-4824-4c7e-8671-
1418af8f3af7). The costs of OSBwere calculated according to
the diagnosis-related group tariffs that are currently used to
fund in patient health services in Italy (http://www.eumed.
it/drg/tariffe_drg.asp).
Sample size
We tested the hypothesis that histological yield obtained with
PDUS-guided CNCB resulted in a higher sensitivity than OSB,
owing to amore significant lymph node tissue biopsied (i.e., the
viable core of malignant lesion was exactly removed). Based on
previous studies, we estimated a sensitivity rate at standard
biopsy of 78% [5] and at PDUS-guided CNCB of 96.5% [14,
18]; hence, a certain number of patients could be
underdiagnosed with OSB approach. To detect more than
10% sensitivity improvement (for the superiority test), 332 pa-
tients were needed, when using a two-sided type I error of 5%
and 99% statistical power. Assuming a dropout rate of 10%, we
set a final sample size of at least 183 patients in each group.
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Randomization
Random allocation sequence was carried out by using a com-
puterized system (generated by the study statistician on the
basis of the procedure outlined elsewhere) [19]. It was based
on a minimization method in which patients were assigned to
the two study groups while ensuring equal distribution on the
basis of sex, age, presence and type of systemic symptoms
(i.e. fever, sweating, and weight loss) and sites of lymph node
enlargement at baseline clinical evaluation.
Patients were asked to sign a consent form before random-
ization, according to the requirements of the Helsinki
declaration.
Statistical analysis
For the statistical evaluations, the χ2 test was performed to
compare proportions for clinical and histological characteris-
tics and complication rate, and the t test was used to compare
the quantitative variables of clinical characteristics, costs, and
waiting times to biopsy between the two groups. P values less
than 0.05 were considered to indicate a significant difference.
Asymptotic 95% confidence intervals for kappa statistic (to
assess the level of agreement in diagnostic opinion among all
three hematopathologists for the 50 samples of the core of
nodal tissue) were computed according to Fleiss et al. [20].
Results
Participants and recruitment
Between 1 January 2009 and 31 December 2015, 376 patients
were randomly assigned either to standard group (N = 187) or
core-needle group (N = 189). All randomized patients re-
ceived allocated biopsy intervention. However, four patients
(2.1%) undergoing PDUS-guided CNCB were excluded for
inadequate samples (thereafter, these cases underwent an
OSB). No other patient was lost to follow-up, nor did any
withdraw their consent to participate in the study when a sec-
ond biopsy was clinically indicated during monitoring. Thus,
a total of 372 patients was analyzed for the primary endpoint
(standard group, N = 187; core-needle group, N = 185).
Twenty-two patients (5.5%) failed during screening. A com-
mon reason for exclusion was contraindications for general
anesthesia (N = 12). Other reasons were the presence of obe-
sity, potential cause of uninterpretable PDUS scans for deep-
seated lymph nodes (N = 6), and refused to participate (N = 4).
A consolidated standard of reporting trials’ (CONSORT) dia-
gram summarizes the study in Figure 1.
Patients in both groups were well-balanced with respect to
clinical characteristics, in particular symptoms suspected for
lymphoma and nodal sites involved at baseline evaluation
(Table 1).
Power Doppler ultrasonographic and core-needle features
The average time required for PDUS examination and core-
needle biopsy was 40 min (range, 30–50 min). Sites of
biopsied lymph nodes were superficial in 140 cases (vs. 160
cases in the standard group) and deep-seated (abdominal or
pelvic regions) in 45 cases (vs. 27 cases in the standard group,
P = 0.02). For each core-needle biopsy, a median of 2 needle
passes (range, 1–4) into the nodal tissue was made. Length of
core-needle specimens varied from 15 to 70 mm (median,
32 mm). Median-estimated volume of acquired tissue was
185 mm3 with a range of 92–430 mm3 (vs. a median volume
of 1458 mm3 with a range of 312–5678 mm3, in the standard
Fig. 1 Flowchart shows patient
selection and follow-up during
the study (CONSORT).
PDUS = power Doppler
ultrasonography
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group). The number of tests (i.e., staining and/or molecular
analyses) performed by pathology on core-needle tissue and
surgical excisional biopsy was similar in the two study groups.
Interobserver reproducibility of histological assessments of
the cores of nodal tissue among the three pathologists had a
kappa score of 0.916 (95%CI: 0.756–1.07). Of the 50 samples
tested for reproducibility, 49 (98%) were classified identically
by the three observers.
Histology
Of the 187 patients undergoing OSB, 149 (80%) cases had
lymph nodes positive for malignancy, and 38 (20%) had
lymph nodes negative for malignancy (described as benign
lymphoid hyperplasia in 37 cases, and sarcoidosis in one case,
with steato-fibrotic and/or necrotic changes in 17 of the cases).
Of the 185 patients undergoing PDUS-guided CNCB (all
with adequate specimens), 172 (93%) cases had lymph nodes
positive for malignancy, and 13 (7%) had lymph nodes nega-
tive for malignancy (benign lymphoid hyperplasia in 10 pa-
tients, Kikuchi-Fujimoto disease in two patients, and sarcoid-
osis in one patient; Table 2).
Overall, the 51 patients with lymph nodes negative for
malignancy (defined as reactive or inflammatory) were ob-
served for a median follow-up of 10 months (range, 1–
24 months). During the follow-up, for 19 of 38 patients in
the standard group, the clinicians required a second lymph
node biopsy, and a malignancy was finally detected. The sec-
ond biopsy, which was performed after a median of 5 months
(range, 1–9 months) from the first biopsy, demonstrated lym-
phoma in 16 patients (five diffuse large B cell lymphomas,
three grade 1 follicular lymphomas, two small lymphocytic
lymphomas, four Hodgkin lymphomas, one mantle cell lym-
phoma, and one nodal marginal zone lymphoma) and meta-
static carcinoma in three patients (Table 3). In contrast, two of
the 13 patients who had had diagnosis of a benign lesion at the
first biopsy in the core-needle group required a second biopsy
(open surgical intervention in both cases) after 6 and 8months,
respectively. Histologic examination showed a malignancy in
both cases (one grade 1 follicular lymphoma and one small
lymphocytic lymphoma) (Table 3).
The definitive histological findings for each case in the two
groups are shown in Tables 2 and 3. Overall, the majority of
patients were suffering from lymphomas (B cell non Hodgkin
lymphoma, 195 cases; Hodgkin lymphoma, 88 cases; T cell
non Hodgkin lymphoma, 12 cases; and metastatic carcinoma,
47 cases).
Accuracy in identifying malignancy
The sensitivity rate of lymph node malignant status was
88.7% [95% confidence interval (CI): 82.9–93] for OSB
(149 of 168 patients with lymph node positive for malignancy
were identified) with a false negative rate of 10.2% (19 of 168
patients with lymph node positive for malignancy were not
identified). By contrast, the sensitivity rate of lymph node
malignant status was 98.8% (95% CI: 95.9–99.9) for PDUS-
guided CNCB (172 of 174 patients with lymph node positive
for malignancy were identified) with a false negative rate of
1.1% (i.e., 2 of 174 patients with lymph node positive for
malignancy were not identified). Therefore, the study objec-
tive to show superiority of PDUS-guided CNCB versus OSB
was achieved, being the sensitivity rate of experimental
Table 1 Baseline characteristics
of patients in the two study groups Standard group Core-needle group P value
Total patients 187 185
Sex
Male 98 (52.4) 86 (46.5) 0.25
Female 89 (47.6) 99 (53.5)
Age, years
Median, (range) 46 (18–79) 42 (17–76) 0.61
Symptoms
Fever 33 (17.6) 31 (16.8) 0.82
Sweat 24 (12.8) 25 (13.5) 0.84
Weight loss 27 (14.4) 26 (14.1) 0.91
Site of clinically suspected lymphadenopathies
Cervical 93 (49.7) 90 (48.6) 0.83
Axillary/pectoral 41 (21.9) 39 (21.1) 0.84
Antero-superior mediastinum 4 (2.1) 3 (1.6) 0.71
Inguinal 28 (15) 30 (16.2) 0.74
Abdomen-pelvic 21 (11.2) 23 (12.4) 0.72
Note: unless otherwise indicated, data are number of patients, with percentage in parentheses
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approach significantly higher than the standard approach
(P < 0.001; Table 4).
Noteworthy, the sensitivity rate of lymph nodes positive for
lymphoma was 98.7% (95%CI: 95.4–99.8) for PDUS-guided
CNCB versus 88.7% (95% CI: 82.3–93.4) for OSB
(P < 0.001). The negative predictive value was 54.3% (95%
CI: 36.6–71.2) for OSB and 84.6% (95% CI: 54.5–98.1) for
PDUS-guided CNCB (P = 0.05). The negative likelihood ratio
was 0.11 (95% CI: 0.07–0.18) for OSB and 0.01 (95% CI:
0.00–0.05) for PDUS-guided CNCB, confirming the value of
the PDUS-guided CNCB for detecting lymphoma.
Waiting time to biopsy
The median waiting time for performance of interventionist
procedure (from biopsy indication to perform itself) in the
core-needle group was 4 days (range, 1–10 days). By contrast,
it was 16 days with a range of 5–34 days in the standard group
(P < 0.001).
Procedure-related complications
Overall, 42 patients, which were in the standard group,
underwent biopsy (cervical-clavicular, 17 cases; medias-
tinum compartments, 4 cases; abdomen-pelvis, 21 cases)
under general anesthesia, with an average hospitalization
of 2.5 days. All other patients underwent biopsy in a
day surgery or outpatient regimen under local
anesthesia.
Patients who received standard biopsy had significantly
more pain, numbness or paresthesia, larger scars,
Table 2 Histologic diagnosis on






B cell neoplasms 84 (44.9) 97 (52.4)
Diffuse large B cell lymphoma 32 (17.1) 38 (20.5)
Follicular lymphoma 25 (13.4) 23 (12.4)
CLL/SLLa 16 (8.6) 18 (9.7)
Mantle cell lymphoma 7 (3.7) 12 (6.5)
Nodal marginal zone lymphoma 3 (1.6) 5 (2.7)
Primary mediastinal (thymic) large B cell lymphoma 1 (0.5) 1 (0.5)
Hodgkin lymphoma 38 (20.3) 46 (24.9)
Nodular sclerosis 25 (13.4) 30 (16.2)
Mixed cellularity 9 (4.8) 11 (5.9)
Nodular lymphocyte predominant 2 (1.1) 2 (1.1)
Lymphocyte-rich 1 (0.5) 1 (0.5)
Lymphocyte-depleted 1 (0.5) 2 (1.1)
T cell neoplasms 4 (2.1) 8 (4.3)
Anaplastic large cell lymphoma, ALK-positive 2 (1.1) 4 (2.2)
T cell lymphoblastic leukemia/lymphoma 1 (0.5) 2 (1.1)
Peripheral T cell lymphoma 1 (0.5) 1 (0.5)
Anaplastic large cell lymphoma, ALK-negative – 1 (0.5)
Metastatic carcinoma 23 (12.3) 21 (11.4)
Nonmalignant findings 38 (20.3) 13 (7)
True-negative 19 (10.1) 11 (5.9)
Benign lymphoid hyperplasia 18 (9.6) 8 (4.3)
Sarcoidosis 1 (0.5) 1 (0.5)
Kikuchi-Fujimoto disease – 2 (1.1)
False-negative 19 (10.1) 2 (1.1)
Benign lymphoid hyperplasiab 19 (10.1) 2 (1.1)
Note: unless otherwise indicated, data are number of patients, with percentage in parentheses
ALK anaplastic lymphoma kinase
a Chronic lymphocytic leukemia/small lymphocytic lymphoma
bWith steato-fibrotic and/or necrotic changes in 17 of the cases
632 Ann Hematol (2017) 96:627–637
lymphorrhea, and wound infection than patients who
underwent PDUS-guided CNCB (Table 5).
Cost analysis
The total cost of the biopsy program was much lower for the
core-needle group than that for the standard group. By using
Italian values for direct costs of interventionist procedures, the
cost for one OSB was €10,393 for major surgery and €3056
for minor surgery, whereas it was €171 for one PDUS-guided
CNCB (including the complete US assessment of superficial
and deep-seated lymph node areas). If the cost of additional
surgical biopsies in the 19 patients (false negative results) of
the standard group and in the two patients (false negative
results) of the core-needle group is considered, the total cost
of lymph node biopsy with standard approach was approxi-
mately 25-fold higher than that with PDUS-guided CNCB
(P < 0.001; Table 6). C. Salvatore wrote the section devoted
to cost analysis and produced Table 6.
Table 3 Findings in the patients who underwent a second lymph node biopsy (all open surgical biopsies) in the two study groups
Patient No. No. of months between
the two biopsies
Biopsy site Sample volume
(mm3)
Histologic diagnosis
First Second First Second First Second
1 2 Cervical Axillary 1597 2154 Benign hyperplasiab Diffuse large B cell lymphoma
2 4 Inguinal Mesenteric 1460 2092 Benign hyperplasiab Diffuse large B cell lymphoma
3 3 Cervical Supraclavicular 3200 4230 Benign hyperplasiab Diffuse large B cell lymphoma
4 5 Supraclavicular Axillary 1539 2129 Benign hyperplasia Diffuse large B cell lymphoma
5 6 Inguinal Iliac 5148 2766 Benign hyperplasia Diffuse large B cell lymphoma
6 1 Cervical Supraclavicular 2860 1769 Benign hyperplasiab Nodular sclerosis—HL
7 3 Cervical Cervical 4512 2870 Benign hyperplasiab Nodular sclerosis—HL
8 3 Axillary Supraclavicular 1955 2350 Benign hyperplasiab Nodular sclerosis—HL
9 4 Inguinal Cervical 2766 2020 Benign hyperplasia Nodular sclerosis—HL
10 5 Cervical Cervical 2030 1980 Benign hyperplasia Follicular lymphoma Grade I
11 6 Cervical Axillary 3240 2563 Benign hyperplasia Follicular lymphoma Grade I
12 7 Inguinal Inguinal 1780 1201 Benign hyperplasiab Follicular lymphoma Grade I
13 6 Cervical Supraclavicular 673 1251 Benign hyperplasiab CLL/SLL
14 8 Cervical Inguinal 1840 2560 Benign hyperplasiab CLL/SLL
15 5 Cervical Supraclavicular 790 1300 Benign hyperplasia Mantle cell lymphoma
16 9 Supraclavicular Axillary 1578 3410 Benign hyperplasia Nodal marginal zone lymphoma
17 1 Cervical Supraclavicular 4370 2531 Benign hyperplasia Metastatic carcinoma
18 2 Inguinal Inguinal 3594 1589 Benign hyperplasia Metastatic carcinoma
19 5 Cervical Supraclavicular 1737 2010 Benign hyperplasiab Metastatic carcinoma
20a 6 Supraclavicular Supraclavicular 230 2130 Benign hyperplasia Follicular lymphoma Grade I
21a 8 Inguinal Cervical 310 1867 Benign hyperplasiab CLL/SLL
Note: Unless otherwise indicated, data are number of patients, with percentage in parentheses
HL Hodgkin lymphoma, CLL/SLL Chronic lymphocytic leukemia/small lymphocytic lymphoma
a Patients #20 and #21 had received power Doppler ultrasonography-guided core-needle cutting biopsy as first lymph node biopsy
bWith intranodal steato-fibrotic and necrotic changes
Table 4 Accuracy of standard biopsy and PDUS-guided CNCB for the







N 149/168 172/174 0.0001
% 88.7 98.8
95% CI 82.9–93.0 95.9–99.9
False-negative
N (%) 19 (10.2) 2 (1.1) 0.0001
Negative predictive value
N 19/38 11/13 0.014
% 50 84.6
95% CI 33.4–66.6 54.5–98.1
Negative likelihood ratio
value 0.11 0.01
95% CI 0.07–0.17 0.00–0.05
CNCB core-needle cutting biopsy, CI confidence interval
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Discussion
Routine biopsy of lymphadenopathies by using core-needle
under imaging guidance in patients with suspicion of lympho-
ma is controversial [1, 2]. Usually, such procedures are re-
served for lymph nodes that are accessible only with surgical
risk or for critical ill patients, and in case of relapse [2]. Most
studies on this issue were retrospective, included an imaging
support based on traditional radiological tools (such as gray-
scale US and CT, which study mostly morphological charac-
teristics, i.e., the dimensional features of lymph node, not
distinguishing between viable tumor and inflammation,
necrosis and/or fibrosis), and have tested the role of
small (≥18-gauge) needle devices with obsolete
Table 5 Biopsy-related







Pain on operated sitea
No 46 (24.6) 130 (70.3) <0.0001
Yes, mild and transient 57 (30.5) 39 (21.1) 0.038
Yes, continuous 84 (44.9) 16 (8.6) <0.0001
Numbness on operated site
No 42 (22.5) 134 (72.4) <0.0001
Yes 145 (77.5) 51 (27.6)
Swelling on operated site
No 50 (26.7) 162 (77.6) 0.0008
Yes 137 (73.3) 23 (12.4)
Esthetic appearance of biopsy scarb
Absent – 185 (100) <0.0001
Acceptable 85 (45.5) –
Unpleasant 102 (54.5) –
Hematomac
No 177 (94.6) 179 (96.8) 0.31
Yes 10 (5.4) 6 (3.2)
Lymphorrhoea
No 178 (85.2) 185 (100) 0.0025
Yes 9 (4.8) –
Wound infection
No 175 (93.6) 185 (100) 0.0005
Yes 12 (6.4) –
Note: unless otherwise indicated, data are number of patients, with percentages in parentheses
a Postoperative pain was evaluated as absent, mild (not requiring analgesia), or continuous (requiring analgesia)
b As judge by the patients themselves 1 month after biopsy
c Temporary hemorrhage, spontaneously resolved
Table 6 Cost analysis of biopsy
procedures Examinations and costs Standard group
(N = 187 patients)
Core-needle group
(N = 185 patients)
Total no. of biopsy procedures 187 185
Unitary cost for biopsy (€)
Major surgerya 10,393 –
Minor surgeryb 3056 –
Complete US assessment of superficial
and deep-seated nodal areas (€)
– 88
US-guided core-needle cutting biopsy (€) – 83
Average cost of biopsy procedure per patient (€) 4115 171
Total cost of additional surgical biopsies due to
false-negative results (€)c
153,445 6112
Total cost of biopsy program (€) 923,016 37,747
aMajor surgery includes mini-cervicotomy, mediastinotomy and laparotomic bioptic procedure
bMinor surgery includes excisional biopsy of superficial lymph nodes
c Total cost of additional surgical biopsies for the four patients randomized in the core-needle group, but excluded
for inadequate samples, was 41,572 €
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configurations [16]. Thus, it is reasonable to investigate
a front line diagnostic combination of new generation
imaging equipment and technologically refined cutting
needle with large gauge [15].
Our randomized study was an examination of two different
interventionist approaches, one surgery-driven (standard arm)
and the other one hematology-driven (experimental arm), in
patients with lymphadenopathies clinically suspected for lym-
phoma. Traditionally, whole lymph nodes are resected when it
is necessary to determine whether a lymphadenopathy is lym-
phoma or some other conditions, such as metastases of a
nonhematological tumor [1, 2]. In our trial, the entire decision
making process for biopsy in the standard arm was left to the
surgeon’s discretion: the selection of the node to be biopsied
was based on physical examination and gray-scale US [17]. In
the daily diagnostic service of our surgery unit, as in others
[21], power Doppler ultrasonographic technology was limited
in its availability for routine clinical practice. In the experi-
mental arm, the selection of the node to be biopsied and
biopsy itself were exclusively based on the expertise of hema-
tologists. In fact, the hematological unit kept a modern US
equipment available and had it run by experienced operators,
who were members of the hematological staff trained in diag-
nostic PDUS [4, 5]. The goal of the study was to maintain
optimal accuracy of the diagnostic work-up of lymphadenop-
athies, while avoiding psychological and physical pain of an
unnecessary surgical intervention.
The primary endpoint in this trial, a greater sensitivity with
the experimental approach, was proven being the comparison
with standard approach significantly advantageous for PDUS-
guided CNCB. The number of cases in which a definite diag-
nosis of malignancy could not be established at first biopsy
Fig. 2 a Inset: low-power image
(H&E, ×1) of a core-needle
biopsy specimen obtained from a
right iliac lymph node: the core-
needles reveal large follicular
nodules closely packed with a
back-to-back arrangement (H&E,
×20). b The neoplastic lymphoid
follicles are composed of a
uniform, small size, cell
population (H&E, ×40). c, d, e
The immunohistochemical stain
strongly highlights CD20 (c),
CD10 (d), and BCL-2 (e) (ABC,
×40). These samples are large
enough to preserve tissue
architecture and to assess the
diagnosis of follicular lymphoma
Fig. 3 a Inset: low-power image (H&E, ×1) of a core-needle biopsy
specimen obtained from a right latero-cervical lymph node: the core-
needle appears fragmented due to an obvious fibrosis (H&E, ×5). b
Higher power views show several Reed-Sternberg cells (H&E, ×40).
The Reed-Sternberg cells are CD30 (c), CD15 (d), and fascin (e)
positive (ABC, ×40). These samples are large enough to preserve tissue
architecture and to assess the diagnosis of nodular sclerosis classical
Hodgkin lymphoma
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was almost 8 times higher on standard tissue specimens than
core-needle material. As a consequence, the clinicians recom-
mended a re-biopsy (OSB) significantly more often in the
standard group than experimental group, also considering
the four patients with inadequate samples randomized in the
core-needle group (19 vs. 6 cases, respectively; P = 0.006).
Not all lymph nodes may be involved by the main disease
entity. There is a risk of removing satellite reactive lymph
nodes, thus missing the primary diagnosis of a malignant dis-
ease present in another node, which is sometimes deeper
seated or even seated in a different anatomic area. An affected
lymph node may also undergo necrosis and/or steato-fibrotic
changes, which could avert the pathologist from the correct
diagnosis. These are all potential sources of inaccuracy in
standard excisional biopsy [5]. In our study, PDUS technology
accurately selected the most suspected target, imaged all nodal
lesion clearly, and simultaneously monitored the entire punc-
ture process (in both superficial and deep-seated regions). The
cutting needle had a diameter of 1.6 mm with ultrathinner tip
and wall, and powered automatic suction. Although the tissue
volume obtained by CNCB was smaller than OSB, the exper-
imental method provided enough tissue for architectural-
morphologic pattern assessment, immunohistochemical stain-
ing, and/or molecular testing (Figs. 2 and 3) [1].
For all secondary endpoints in this trial, the comparison
was significantly disadvantageous for excisional biopsy.
Compared with PDUS-guided CNCB, standard approach
had significantly more waiting time to allocated intervention-
ist procedure, considerably higher amounts of biopsy-related
complications (analgesia required for postoperative pain was
about 5-fold higher), and extraordinarily higher costs for the
National Healthcare System (performance of one biopsy was
24-fold more expensive with standard approach).
Our study suffers from three major limitations. First, this
trial was conducted in one single center. Therefore, studies
from other institutions are needed to assess (1) interobserver
and interequipment PDUS variability; (2) core-needle speci-
men quality reproducibility, e.g., tissue harvested, size and
preservation; and (3) concordance by pathologists in diagnos-
ing and subtyping lymphoma on core-needle material.
Second, a bias error could have been committed due to a more
accurate selection of nodal target to be biopsied in the core-
needle group leading the study toward a better sensitivity for
experimental arm than standard arm. A factor that may have a
strong influence to explain such bias is the high specialization
(derived from long and extensive experience) [4–8] of hema-
tology team to identify the right lymph node and to biopsy it,
as compared to the surgeons. Finally, the rate of failure with
PDUS-guided CNCB was 1.6% (6/376 patients randomly al-
located to core-needle biopsy procedure). In four patients
(those with inadequate samples), stiffened tissue of nodular
sclerosis Hodgkin lymphoma (documented at re-biopsy)
which was seated in subclavicular area (a particular hindered
region) led to the sampling error of CNCB. For the two false
negative results (benign lymphoid hyperplasia), the final di-
agnosis (at second biopsy) was conclusive for small lympho-
cytic indolent non-Hodgkin lymphoma, suggesting that in
some instances, there is a need of a large amount of lymph
node tissue for correct histological assessment.
To the best of our knowledge, this study is the first to
compare in a randomized fashion the sensitivity of imaging-
guided CNCB and OSB in detecting lymphoma. Under opti-
mal study conditions (avoiding patients with obesity), with
modern US equipment and an experienced operator, core-
needle biopsy is a reliable and cost-effective diagnostic pro-
cedure [22]. Histological patterns of lymphoma are recogniz-
able in core material and are useful in diagnosing and
subtyping according to the current WHO classification of tu-
mors of haematopoietic and lymphoid tissues [1, 15]. A 16-
gauge cutting needle is recommended, and at least two passes
yielding two tissue cores, with total length of 30–60 mm
should be taken. CNCB is less traumatic and well tolerated
by patients. It should be recommended as first-line procedure,
for both superficial and deep-seated lymph nodes, for patients
with a suspected lymphoma, and not merely for patients with
poor medical condition when surgical intervention is not pos-
sible or to document relapse.
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